INmune Bio Inc (INMB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
INmune Bio Inc stock (INMB) is currently trading at $1.18. INmune Bio Inc PS ratio (Price-to-Sales) is 622.10. Analyst consensus price target for INMB is $7.00. WallStSmart rates INMB as Sell.
- INMB PE ratio analysis and historical PE chart
- INMB PS ratio (Price-to-Sales) history and trend
- INMB intrinsic value — DCF, Graham Number, EPV models
- INMB stock price prediction 2025 2026 2027 2028 2029 2030
- INMB fair value vs current price
- INMB insider transactions and insider buying
- Is INMB undervalued or overvalued?
- INmune Bio Inc financial analysis — revenue, earnings, cash flow
- INMB Piotroski F-Score and Altman Z-Score
- INMB analyst price target and Smart Rating
INmune Bio Inc
📊 No data available
Try selecting a different time range
Smart Analysis
INmune Bio Inc (INMB) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
INmune Bio Inc (INMB) Key Strengths (2)
Revenue surging 257.10% year-over-year
Trading at 1.24x book value, attractively priced
Supporting Valuation Data
INmune Bio Inc (INMB) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 622.1x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
INmune Bio Inc (INMB) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Price/Book. Valuation metrics including Price/Book (1.24) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 257.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (622.10) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -155.80%, Operating Margin at -69724.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -155.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 257.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
INMB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
INMB's Price-to-Sales ratio of 622.10x sits near its historical average of 695.77x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 18% below its historical high of 755.02x set in Mar 2026, and 0% above its historical low of 622.1x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for INmune Bio Inc (INMB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
INmune Bio Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 50,000 with 257% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 257% YoY, reaching 50,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 9774% of revenue (5M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can INmune Bio Inc maintain 257%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact INmune Bio Inc.
Bottom Line
INmune Bio Inc is a high-conviction growth story with revenue accelerating at 257% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:23:19 AM
About INmune Bio Inc(INMB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California.